Long-term treatment with oral enoximone for chronic congestive heart failure: The European experience

Treese, N; Erbel, Raimund; Pilcher, J. F.; Choraria, S.; Rhein, Siegfried; Dieterich, H. A.; Meyer, Jürgen

doi:10.1016/0002-9149(87)90533-9

Cited by 14 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PDE inhibitor enoximone has been extensively described during both intravenous and oral administration [6,9,[16][17][18][19]. Like the other phosphodiesterase inhibitors, amrinone and milrinone, enoximone improves cardiac pump function due to a reduction of left and right ventricular filling pressures, arteriolar vasodilation, a decrease in systemic vascular resistance, and a concomitant increase in left ventricular dp/dt [20].…”

Section: Hemodynamic Effectsmentioning

confidence: 99%

Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease—relation to plasma concentration

Mitrović

Petrovic

Bahavar

et al. 1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The hemodynamic and antiischemic effects of a 150-mg single oral dose of the PDE inhibitor enoximone were correlated with the plasma levels of enoximone and its sulfoxide metabolite. Twenty-one patients with angiographically documented coronary artery disease were investigated by exercise testing 1 and 2 hours after drug administration. The control group consisted of 15 patients with proven coronary artery disease and stable reproducible angina pectoris on exercise. The enoximone group included 14 responders with therapeutic plasma concentrations 2 hours after drug intake and significantly reduced mean pulmonary artery pressures on exercise (from 42.4 +/- 8.6 to 30.9 +/- 11.2 mmHg, p less than 0.05). Compared to basal exercise values, responders showed a reduced ST-segment depression by 1 hour after drug intake (2.1 +/- 1.2 vs. 1.3 +/- 3 mm, p less than 0.05) and minimal values after 2 hours (0.9 +/- 1.0 mm, p less than 0.01) at comparable workloads. There were no significant changes in heart rate, blood pressure, cardiac output, and systemic vascular resistance. No significant improvement in the hemodynamic parameters and ST-segment depression was found in nonresponders with plasma concentrations below 100 ng/ml and 500 mg/ml for enoximone and its metabolite, respectively. In summary, oral administration of enoximone in patients with coronary artery disease led to favorable acute hemodynamic and antiischemic effects at sufficiently high plasma levels of enoximone and its sulfoxide metabolite.

show abstract

Section: Hemodynamic Effectsmentioning

confidence: 99%

Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease—relation to plasma concentration

Mitrović

Petrovic

Bahavar

et al. 1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

show abstract

“…Both intravenous and oral enoximone produce acute improvements in haemodynamics (52)(53)(54)(55). The long-term efficacy of oral enoximone and its effects on mortality are still to be established (56)(57)(58)(59)(60)(61)(62)(63)(64).…”

Section: Enoximonementioning

confidence: 99%